New drug for cystic fibrosis does not significantly interfere with another drug that prevents organ rejection
Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants
Evidence of early increased sialylation of airway mucins and defective mucociliary clearance in CFTR-/- deficient piglets
Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation
“Mild” CFTR genetic variants might be associated with a lower than expected probability of developing CF